Sarepta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SRPT and other ETFs, options, and stocks.

About SRPT

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA. 

CEO
Douglas S. Ingram
CEODouglas S. Ingram
Employees
1,372
Employees1,372
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1980
Founded1980
Employees
1,372
Employees1,372

SRPT Key Statistics

Market cap
5.69B
Market cap5.69B
Price-Earnings ratio
25.07
Price-Earnings ratio25.07
Dividend yield
Dividend yield
Average volume
2.53M
Average volume2.53M
High today
$60.15
High today$60.15
Low today
$55.99
Low today$55.99
Open price
$57.22
Open price$57.22
Volume
3.76M
Volume3.76M
52 Week high
$173.25
52 Week high$173.25
52 Week low
$55.99
52 Week low$55.99

SRPT News

TipRanks 2h
Sarepta Therapeutics: Undervalued Stock with Strong US Market Potential Despite EMA Hold

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating yesterday. Joseph Schwartz has given his Buy ra...

Benzinga 13h
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

In March, Sarepta Therapeutics, Inc. SRPT shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duch...

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
TipRanks 19h
Sarepta study pause brings approvability risk in Europe, says RBC

RBC Capital keeps a Sector Perform rating on Sarepta (SRPT) after the company’s partner Roche (RHHBY) announced the European Medicines Agency imposed clinical h...

Analyst ratings

83%

of 23 ratings
Buy
82.6%
Hold
17.4%
Sell
0%

More SRPT News

TipRanks 24h
Sarepta price target lowered to $70 from $99 at Deutsche Bank

Deutsche Bank analyst David Hoang lowered the firm’s price target on Sarepta (SRPT) to $70 from $99 and keeps a Hold rating on the shares ahead of the Q1 report...

Simply Wall St 2d
Could The Market Be Wrong About Sarepta Therapeutics, Inc. Given Its Attractive Financial Prospects?

It is hard to get excited after looking at Sarepta Therapeutics' (NASDAQ:SRPT) recent performance, when its stock has declined 49% over the past three months. H...

Could The Market Be Wrong About Sarepta Therapeutics, Inc. Given Its Attractive Financial Prospects?
TipRanks 3d
Marks’ Resignation Is a Blow for Biotech Industry, Says RBC Analyst

Biotech stocks took a hit after the sudden resignation of Dr. Peter Marks, head of the FDA’s Center for Biologics Evaluation and Research (CBER). Shares of Mode...

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.